GH Research (NASDAQ:GHRS) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of GH Research (NASDAQ:GHRS) in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has a $40.00 price target on the stock.

Separately, Canaccord Genuity Group dropped their target price on GH Research from $31.00 to $28.00 and set a “buy” rating on the stock in a research note on Monday, November 18th.

GH Research Trading Down 4.6 %

NASDAQ GHRS opened at $8.57 on Friday. The firm’s fifty day simple moving average is $8.44 and its two-hundred day simple moving average is $9.17. The firm has a market capitalization of $445.88 million, a P/E ratio of -10.85 and a beta of 0.84. GH Research has a 12-month low of $5.50 and a 12-month high of $14.99.

Institutional Inflows and Outflows

An institutional investor recently raised its position in GH Research stock. RA Capital Management L.P. lifted its stake in shares of GH Research PLC (NASDAQ:GHRS) by 1.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,686,689 shares of the company’s stock after purchasing an additional 85,000 shares during the period. RA Capital Management L.P. owned 12.85% of GH Research worth $44,734,000 as of its most recent SEC filing. 56.90% of the stock is owned by institutional investors.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).